10/08/2018 Update on review of valsartan medicines due to detection of NDMA EMA reviewing valsartan produced by another company Zhejiang Tianyu As part of the ongoing review of valsartan medicines, EMA has learnt that low levels of N-nitrosodimethylami… read more
The European Securities and Markets Authority (ESMA) has updated today its validation rules regarding the European Markets Infrastructure Regulation (EMIR) with regards to the revised technical standards on reporting under Article 9 of EMIR. The amendments will be applicable from … read more
The European Securities and Markets Authority (ESMA) has updated today its validation rules regarding the European Markets Infrastructure Regulation (EMIR) with regards to the revised technical standards on reporting under Article 9 of EMIR. The amendments will be applicable from … read more
The European Securities and Markets Authority (ESMA) is correcting today its Suspensions File in relation to its Double Volume Cap (DVC) data, originally published on 7 August 2018, as required under the Markets in Financial Instruments Regulation (MiFIR). The original Suspensions … read more
The European Securities and Markets Authority (ESMA) is correcting today its Suspensions File in relation to its Double Volume Cap (DVC) data, originally published on 7 August 2018, as required under the Markets in Financial Instruments Regulation (MiFIR). The original Suspensions … read more